WHO ICTRP trial

A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib…

JPRN-jRCT2031230073 · Japan Primary Registries Network (JPRN) · Not Recruiting

Key facts

Trial ID JPRN-jRCT2031230073
Public title A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - The COASTAL Study
Scientific title A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - The COASTAL Study
Primary sponsor Hanaya Miyoko
Secondary sponsors Kyowa Kirin Co., Ltd.
Registry Japan Primary Registries Network (JPRN)
Recruitment status Not Recruiting
Study type Interventional
Phase 3
Countries Argentina;Japan;Australia;Japan;Austria;Japan;Belgium;Japan;Canada;Japan;Colombia;Japan;Czech Republic;Japan;France;Japan;Georgia;Japan;Germany;Japan;Greece;Japan;Hungary;Japan;Ireland;Japan;Italy;Jap…
Conditions Follicular Lymphoma, Marginal zone lymphoma
Interventions Subjects who meet the eligibility criteria will be randomly assigned in a 1:1 ratio to one of the treatment arms: - Arm 1: R plus zandelisib - Arm 2: R plus chemotherapy (CHOP or B) Zandelisib: Administered in a 28-day cycle. Zandelisib…
Registration date May 15, 2023
Target size 534
Secondary IDs NCT04745832
Registry page jrct.niph.go.jp

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations